The United States Patent and Trademark Office (USPTO) has granted U.S. patent 12,122,741, which claims the composition of matter of lead preclinical candidates in Cybin Inc’s CYBN CYB005 phenethylamines program.
The company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for Central Nervous System (CNS) disorders.
In addition, the company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT1A and 5-HT2Creceptor agonists.
“The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the breadth of innovative development work beyond our clinical tryptamine programs,” said Doug Drysdale, CEO of Cybin.
“Non-hallucinogenic 5-HT receptor agonists have garnered a great deal of attention in recent years, and we are eager to continue exploring their clinical potential in CNS disorders. While our primary focus remains on our clinical-stage psychiatry programs, CYB003 and CYB004, we believe that other programs like CYB005 that target CNS disorders have the potential to address significant unmet medical needs.”
In August, Cybin held a Type B Initial Breakthrough Therapy Meeting with the FDA and said it plans to initiate its Phase 3 pivotal trial of CYB003 for the adjunctive treatment of major depressive disorder in late summer of 2024.
12-month efficacy results from the Phase 2 study of CYB003 in major depressive disorder are expected in the fourth quarter of 2024.
In July, the company received U.S. patent no. 12,042,564, providing additional patent protection for the CYB004 program under development for Generalized Anxiety Disorder (GAD).
Price Action: CYBN stock closed at $10.93 on Wednesday.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
